The Leadership Core provides the overall context for the translational activities of the SPORE and builds on established interdisciplinary collaborations. Dr. Porter and Dr. Cheever, Co-PIs of the SPORE, will co-direct the Core and lead an Executive Committee (EC), composed of all Project and Core leaders and breast cancer patient advocates, primarily responsible for overall planning and evaluation. The EC will be advised on scientific direction, planning and evaluation of the translational progress of SPORE projects and activities by both an External Advisory Board (EAB), which includes three national SPORE leaders, and an Internal Advisory Board (lAB), which include two SPORE leaders. To maintain a high degree of translational research focus to all SPORE activities, the EC will meet and interact regularly with the SPORE Career Development Program (CDP) and Developmental Research Program (DRP) committees, and the SPORE Statistical Working Group (SWG).
The aims of the Administrative Core are to: 1. Provide oversight of all SPORE activities to meet the scientific and administrative needs of the individual research projects and cores 2. In consultation with EAB members, integrate new projects into the SPORE 3. Provide an organizational structure within the FHCRC/UW Cancer Consortium (Consortium), which a. promotes interaction between interdisciplinary investigators, in and outside of the SPORE b. evaluates progress towards translational goals c. encourages, selects and guides new research and developmental projects d. provides career mentorshlp and entry of women and minorities into the field of breast cancer research 4. Promote SPORE-SPORE interactions, within and outside the Consortium 5. Provide fiscal management of grant funds and records in compliance with all regulations and requirements, including Radiation Safety, Animal Care, and Protection of Human Subjects 6. Communicate and consult with NCI project officers and staff in preparation of required progress reports, publications and regulatory documents
The structure and make up of the Leadership Core brings diverse groups together for planning, development of new projects, career development and support and offers a plan for evaluation of the success in building a truly translational breast cancer research program within the SPORE mechanism.
|Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655|
|Amornsiripanitch, Nita; Nguyen, Vicky T; Rahbar, Habib et al. (2017) Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers. J Magn Reson Imaging :|
|Balakrishnan, Ashwini; Goodpaster, Tracy; Randolph-Habecker, Julie et al. (2017) Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res 23:3061-3071|
|Sommermeyer, D; Hudecek, M; Kosasih, P L et al. (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30:492-500|
|Busch, Dirk H; Fräßle, Simon P; Sommermeyer, Daniel et al. (2016) Role of memory T cell subsets for adoptive immunotherapy. Semin Immunol 28:28-34|
|Paszkiewicz, Paulina J; Fräßle, Simon P; Srivastava, Shivani et al. (2016) Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 126:4262-4272|
|Liu, Lingfeng; Sommermeyer, Daniel; Cabanov, Alexandra et al. (2016) Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol 34:430-4|
|Rahbar, Habib; Parsian, Sana; Lam, Diana L et al. (2016) Can MRI biomarkers at 3 T identify low-risk ductal carcinoma in situ? Clin Imaging 40:125-9|
|Rahbar, Habib; McDonald, Elizabeth S; Lee, Janie M et al. (2016) How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis? Acad Radiol 23:768-73|
|Robinson, Michael A; Graham, Daniel J; Morrish, Fionnuala et al. (2016) Lipid analysis of eight human breast cancer cell lines with ToF-SIMS. Biointerphases 11:02A303|
Showing the most recent 10 out of 52 publications